Physician profile
Maja Davidson
NPI 1841555901
$4,368.20
in general payments reported to CMS, 2019-2025
35 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $519 · 2021: $47.74 · 2022: $406 · 2023: $1,060 · 2024: $1,303 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $617.07 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $500.00 | 2020 | |
| Abbott Laboratories | $395.25 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Abbvie INC. | $320.98 | 2022-2025 | Synthroid |
| Insulet Corporation | $259.31 | 2021-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $233.94 | 2022-2024 | |
| Medtronic, INC. | $224.83 | 2022-2024 | Minimed 780g |
| Radius Health, INC. | $224.50 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.87 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $159.56 | 2023-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $149.84 | 2022-2023 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $138.76 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $133.20 | 2022-2025 | Ozempic, Rybelsus |
| Embecta Corp. | $102.63 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Amneal Pharmaceuticals LLC | $90.90 | 2023-2025 | Unithroid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $77.45 | 2025 | Korlym |
| Sequel Med Tech, LLC | $71.19 | 2025 | Twiist |
| Angiodynamics, INC. | $68.03 | 2022 | |
| Ascendis Pharma Endocrinology INC | $52.40 | 2023-2025 | Yorvipath |
| Almatica Pharma LLC | $41.97 | 2024-2025 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $41.10 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $39.58 | 2023-2024 | Signifor Lar, Isturisa |
| Lifescan, INC. | $38.85 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.09 | 2025 | |
| Verity Pharmaceuticals INC. | $19.38 | 2025 | Tlando |
| Mannkind Corporation | $18.91 | 2020 | |
| Beta Bionics, INC. | $18.78 | 2024 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $18.41 | 2022 | |
| Nevro Corp. | $16.53 | 2023 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $15.19 | 2023 | |
| Echosens North America, INC. | $14.90 | 2025 | Fibroscan |
| Becton, Dickinson and Company | $14.08 | 2019 | |
| Globus Medical, INC. | $13.92 | 2025 | Senza |
| Janssen Pharmaceuticals, INC | $11.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maja Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.